Iridex to Participate in Fireside Chat with Stifel Equity Research
Iridex Corporation (NASDAQ: IRIX), a leader in ophthalmic laser-based medical products, announced its participation in a fireside chat with Stifel's equity research analyst.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Iridex Corporation (NASDAQ: IRIX), a leader in ophthalmic laser-based medical products, announced its participation in a fireside chat with Stifel's equity research analyst. This discussion is scheduled for December 8, 2022, at 9:00 a.m. PT / 12:00 p.m. ET. The event will be accessible via a live and archived webcast on the Company’s website. Iridex specializes in innovative laser systems for treating glaucoma and retinal diseases, using its proprietary MicroPulse® technology. The Company's products are distributed both in the U.S. and over 100 countries worldwide.
Details
News Market Reaction – IRIX
The recorded move for IRIX in the trading session of this news was -3.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in a fireside chat with its covering equity research analyst from Stifel.
Management is scheduled to discuss the business on Thursday, December 8, 2022 at 9:00 a.m. PT / 12:00 p.m. ET. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com.
About Iridex
Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.
Investor Relations Contact:
Philip Taylor
(415) 937-5406
investors@iridex.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.